FMP
2seventy bio, Inc.
TSVT
NASDAQ
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a collaboration arrangement with Bristol-Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.
3.92 USD
-0.21 (-5.36%)
About
ceo
Mr. William D. Baird III, M.B.A.
sector
Healthcare
industry
Biotechnology
website
https://www.2seventybio.comexchange
NASDAQ
Description
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a collaboration arrangement with Bristol-Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.
CIK
0001860782
ISIN
US9013841070
CUSIP
901384107
Address
60 Binney Street
Phone
339 499 9300
Country
US
Employee
274
IPO Date
Nov 3, 2021
TSVT Financial Summary
CIK
0001860782
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
901384107
ISIN
US9013841070
Country
US
Price
3.92
Beta
1.79
Volume Avg.
308.75k
Market Cap
201.87M
Shares
-
52-Week
1.535-6.4
DCF
0
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-1.28
P/B
-
Website
https://www.2seventybio.com
Historical Prices
We are unable to load the chart at this time.
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
Upgrades and Downgrades
We are unable to load this data!
People Also Watch
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest TSVT News
It looks like there's no news available.
